Ekaterina Sanarova

Dr. Ekaterina Sanarova

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LNLudmila Nikolaeva
Ludmila Nikolaeva
NONatalia Oborotova
Natalia Oborotova
NBNatalia Bunyatyan
Natalia Bunyatyan
XZXi Zhang
Xi Zhang
ESEkaterina Sanarova
Ekaterina Sanarova
APAlevtina Polozkova
Alevtina Polozkova
Despite the rapid development of medical technologies, chemotherapy treatment still occupies an important place in clinical oncology. In this regard, the current research in this area focuses on the synthesis of new highly effective antitumor substances that have minimal side effects and the development of stable pharmaceutical formulations (PF) on their basis. In order to solve this problem, the I. Ya. Postovsky Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences actively sought for original substances, namely, nitrosourea (NU) derivatives, one of the most promising classes of anticancer drugs. As a result of this research, a novel NU derivative was synthesized, namely ormustine, which showed high antitumor activity in preliminary preclinical trials. It is now crucial to develop an ormustine pharmaceutical formulation. Conducted technological studies showed that the most suitable solvent for the drug substance is 0.1 M hydrochloric acid, which ensures its rapid dissolution by ultrasonic treatment. A significant reduction in the concentration of the active ingredient during the storage of the solution required the development of a technique of its lyophilization and the selection of a shaper such as a Kollidon 17 PF. Upon completion of the development of a pharmaceutical formulation of ormustine, its stability after lyophilization was demonstrated, and a sufficient amount of the drug has been acquired for preclinical research.

18 October 2022 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
ESEkaterina Sanarova
Ekaterina Sanarova
ALA. V. Lantsova
A. V. Lantsova
LNL. L. Nikolaeva
L. L. Nikolaeva
NON. A. Oborotova
N. A. Oborotova

1 May 2015 in Nanotechnologies in Russia
Verified
Journal Article
Closed access
PDF file
ESEkaterina Sanarova
Ekaterina Sanarova
ALA. V. Lantsova
A. V. Lantsova
APA. P. Polozkova
A. P. Polozkova
OOO. L. Orlova
O. L. Orlova
IMI. G. Meerovich
I. G. Meerovich
NON. A. Oborotova
N. A. Oborotova
The implementation of liposome delivery systems ensures the intravenous introduction of hydrophobic photosensitizers used in the treatment of tumors by the photodynamic therapy method with their preservation in a therapeutically effective nonaggregated form and high accumulation selectivity in the tumor. Phthalocyanines are one of the fastest growing classes of antineoplastic photosensitizers, most of which are hydrophobic compounds. In this study the authors have developed the unique composition and technology of preparing the lyophilized liposomal formulation of infrared photosensitizer: aluminum hydroxide tetra-3-phenylthiophtalocyanine (Thiosens). At the stage of biological experiments on model mouse tumors, the preservation of high accumulation selectivity in the tumor (selectivity index is higher than 4) and antineoplastic effectiveness (inhibition of tumor growth is from 70 to 94%) were found during the transition from the previously studied model dosage form to the created lyophilized liposomal one. To estimate chemical and pharmaceutical criteria and the photodynamic efficiency of the photosensitizer on a number of transplanted mice tumor models in vivo, we have conducted a preclinical study which has demonstrated the stability of antitumor activity and quality consistency of the developed dosage form for one and a half years.

15 January 2020 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
ALA. V. Lantsova
A. V. Lantsova
LBL. M. Borisova
L. M. Borisova
GMG. A. Meerovich
G. A. Meerovich
NBN. D. Bunyatyan
N. D. Bunyatyan
YOYu. V. Olefir
Yu. V. Olefir
LNLudmila Nikolaeva
Ludmila Nikolaeva

1 October 2023 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
ESEkaterina Sanarova
Ekaterina Sanarova
ALA. V. Lantsova
A. V. Lantsova
LNL. L. Nikolaeva
L. L. Nikolaeva
NON. A. Oborotova
N. A. Oborotova
YLYa. E. Litvinenko
Ya. E. Litvinenko
NSN. L. Solov’eVa
N. L. Solov’eVa

1 December 2013 in Russian Journal of General Chemistry
Verified
Journal Article
Closed access
PDF file
NON. A. Oborotova
N. A. Oborotova
ESEkaterina Sanarova
Ekaterina Sanarova
Foreign and domestic research on nanostructured formulations of known and new anticancer drugs provide evidence in favor of improved physicochemical (solubility, stability on storage) and therapeutic characteristics (efficacy, stability in the body, selectivity of accumulation in pathological sites, toxicity) of the most part of studied formulations.